BioVie Phase 2 trial links Long COVID biomarker subgroups to different bezisterim responses
BIVI•BioVie presented exploratory findings from its 203-participant Phase 2 ADDRESS-LC trial: overall efficacy outcomes did not reach statistical significance over 12 weeks, while some biomarker subgroups showed significant improvement in specific symptoms.
1. Trial subgroup findings
The trial showed improvement trends, but no efficacy outcomes reached statistical significance in the overall population over 12 weeks. Patients with elevated inflammation showed significant cognitive improvement, while those with low white blood cell levels had larger treatment effects on fatigue and post-exertional malaise. Bezisterim significantly reduced circulating neuropeptide Y; safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group.




